Basic product information

• Medicine name: Dasatinib
• Common forms: Tablets (strength varies by product; strengths may include 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, depending on brand and availability)
• Drug class: Tyrosine kinase inhibitor (TKI)
• ATC classification (general): L01XE (anti-neoplastic kinase inhibitors)
• What it treats: Selected cases of CML and Ph+ ALL where the cancer is driven by BCR-ABL signalling

Brand names and tablet strengths can differ. Always check the strength written on your pack and follow the dosing instructions provided for your specific regimen.

How dasatinib works (mechanism of action)

Dasatinib targets specific enzymes called tyrosine kinases involved in cancer cell growth and survival. In many CML and Ph+ ALL cases, cancer cells carry a genetic abnormality known as the Philadelphia chromosome, which produces a fusion protein called BCR-ABL. This protein continuously sends “growth signals”.

By inhibiting BCR-ABL and related kinases, dasatinib helps:

• reduce cancer cell signalling and proliferation
• promote more controlled cell survival
• improve blood and bone marrow responses over time (in suitable patients)

Because it targets signalling pathways, dasatinib is often described as targeted therapy rather than classic chemotherapy.

Typical use in Australia

Dasatinib is used for patients with:

• Chronic myeloid leukaemia (CML) in certain phases (including chronic phase and accelerated phase)
• Philadelphia chromosome–positive acute lymphoblastic leukaemia (Ph+ ALL), usually in particular patient groups (e.g., after prior treatment or based on disease characteristics)

Which option is appropriate depends on disease phase, prior treatments, mutation testing, overall health, and treatment goals. Your treating team will match the medicine choice to your specific diagnosis.

Pharmacokinetics (how the body handles dasatinib)

Understanding pharmacokinetics can help patients understand timing and consistency.

If you miss a dose or change habits (for example, starting a new supplement), exposure can vary. Consistency and careful review of interactions are important.

Timing and how to take dasatinib

Many dasatinib regimens are taken once daily, usually at approximately the same time each day. Your dosing schedule may differ based on your regimen, treatment phase, and tolerance.

General timing tips

• Choose a consistent time: Taking at the same time each day helps maintain steadier drug levels.
• Don’t change the schedule: Unless your clinician advises otherwise, keep your daily routine stable.
• Swallow whole: Follow product instructions on whether tablets must be swallowed whole or if any specific handling is required.
• Use a pill organiser carefully: If you split medications across days, ensure you organise only according to your exact regimen.

If you miss a dose

Missing doses may reduce effectiveness. Practical guidance can differ by regimen, so follow the instructions provided with your medicine or by your healthcare team. In general, avoid taking extra doses to “catch up” unless instructed. If you’re unsure, contact your treating team or pharmacy for advice.

When to start noticing effects

Response to TKIs can develop over weeks to months. Some patients may experience symptom changes earlier, while measurable blood or molecular responses often require repeated monitoring over time.

Food interactions (what to consider)

Food can influence absorption of some cancer medicines, including TKIs. For dasatinib, the effect of food may be clinically relevant. The safest approach is to follow the specific instructions for your product.

• Follow pack instructions: If your medicine guide advises taking with or without food, follow it exactly.
• Be consistent day to day: Try to maintain the same relationship to meals (for example, always with food or always on an empty stomach) unless your clinician changes advice.
• Discuss reflux/antacid use: Medicines that reduce stomach acid can interact with absorption for many TKIs. See the next sections for medicine interactions.

If you have swallowing difficulties, severe nausea, or significant appetite changes during treatment, tell your healthcare team.

Alcohol interactions and lifestyle considerations

Alcohol is not usually listed as a direct interaction for every patient, but it can affect the liver and worsen side effects such as fatigue, nausea, dizziness, and dehydration. Because dasatinib is metabolised by the liver, heavy alcohol use may increase risk of liver-related problems.

Practical guidance

• Limit alcohol: If you drink, keep it modest and consistent with your clinician’s advice.
• Avoid binge drinking: This increases risk of liver injury and other complications.
• Monitor symptoms: If you experience worsening nausea, abdominal discomfort (especially right upper abdomen), yellowing of skin/eyes, or dark urine, seek medical advice promptly.

Medicine interactions (including acid-reducing medicines)

Interactions matter for dasatinib because drug levels can change when medicines that affect liver enzymes or stomach acidity are used together. Always provide your full medication list (including over-the-counter medicines, vitamins, herbal products) to your pharmacy and treating team.

Key interaction categories

• Strong CYP3A4 inhibitors: May increase dasatinib levels and side effects. Examples include certain antifungals and some antibiotics (specific examples should be checked with a pharmacist).
• Strong CYP3A4 inducers: May reduce dasatinib levels and effectiveness. Examples include certain seizure medicines and some herbal products (e.g., St John’s wort).
• Acid-reducing medicines: Proton pump inhibitors (PPIs), H2 blockers, and some antacids can affect absorption. Your clinician may advise specific timing or alternatives.
• Other QT-prolonging medicines: Dasatinib may influence heart rhythm in susceptible patients, especially if combined with other QT-prolonging drugs.
• Anticoagulants and anti-platelet medicines: Bleeding risk can be affected by overall blood counts and concurrent medicines.

If you need new medicines (for example, antibiotics for an infection or antifungals for a fungal condition), ask the pharmacy to check compatibility before you start.

Dosing overview (general information)

Dasatinib dosing depends on the indication (CML phase, Ph+ ALL), prior therapies, and patient tolerance. Exact dosing regimens vary and may be adjusted over time.

Important: Dosing adjustments are commonly needed for side effects such as low blood counts, fluid retention, or other tolerability issues. Do not alter your dose without clinician advice.

Indications (what it is approved/used for)

Dasatinib is indicated for certain patients with:

• Chronic myeloid leukaemia (CML) that is Philadelphia chromosome–positive
• Accelerated phase CML that is Philadelphia chromosome–positive
• Philadelphia chromosome–positive acute lymphoblastic leukaemia (Ph+ ALL) in eligible patient groups

Eligibility and treatment phase matter. Your healthcare team will interpret results such as blood counts and molecular testing to determine the most appropriate regimen.

Safety profile (side effects) and when to seek help

Like all medicines, dasatinib can cause side effects. Many are manageable, but some can be serious. Below is a patient-friendly overview of common and important risks.

Common side effects

• Low blood counts (myelosuppression): may lead to increased risk of infection, anaemia (tiredness/shortness of breath), and bleeding/bruising due to low platelets
• Fatigue
• Nausea and/or diarrhoea
• Headache
• Rash or dry skin
• Muscle or bone pain
• Fluid retention in some patients (for example swelling in legs)

Serious or important risks

• Pleural effusion (fluid around the lungs): can cause shortness of breath, cough, chest tightness, or reduced exercise tolerance.
• Cardiac rhythm changes: symptoms may include palpitations, dizziness, fainting, or severe light-headedness.
• Pulmonary arterial hypertension (PAH) (uncommon but important): symptoms can include progressive breathlessness, fatigue, chest discomfort, or swelling.
• Liver changes: watch for yellow skin/eyes, dark urine, severe abdominal pain, or persistent vomiting.
• Severe infection: fever, chills, or feeling very unwell can be urgent, especially when blood counts are low.
• Bleeding: unexpected bruising, nosebleeds, blood in urine/stool, or prolonged bleeding should be assessed promptly.

When to seek urgent medical help

Seek urgent care or contact emergency services if you experience:

• trouble breathing at rest or worsening shortness of breath
• fainting, severe dizziness, or chest pain
• high fever or signs of serious infection
• black/tarry stools, vomiting blood, or heavy/uncontrolled bleeding
• rapid swelling of face/lips or signs of severe allergic reaction

Practical use tips (making treatment easier)

1) Keep regular monitoring appointments

Dasatinib treatment commonly involves regular blood tests to track blood counts and check organ function (e.g., liver enzymes). Molecular monitoring may also be performed to assess response over time.

2) Protect yourself from infection

• Practice good hand hygiene.
• Avoid close contact with people who are unwell.
• Ask your healthcare team about vaccines and timing (especially live vaccines).
• Report fever promptly, as it can be more serious when blood counts are low.

3) Watch for fluid-related symptoms

Contact your clinician promptly if you notice swelling in the legs/feet or new/worsening shortness of breath or dry cough. These can signal fluid retention or pleural effusion.

4) Manage common stomach side effects

• Take your dose as instructed in relation to food.
• Stay hydrated, especially if diarrhoea occurs.
• Discuss persistent nausea or diarrhoea, as dose adjustments or supportive medicines may be needed.

5) Oral health and mouth care

If you develop mouth sores, painful swallowing, or oral discomfort, seek advice early. Good oral hygiene and early management can reduce complications.

6) Contraception and pregnancy planning (general safety)

Dasatinib can be harmful to an unborn child. If pregnancy is possible, discuss contraception planning with your healthcare team before starting. If you become pregnant or plan pregnancy, seek urgent medical advice to discuss risks and options.

Alternative options (other medicines in the same setting)

There are other tyrosine kinase inhibitors used for CML and Ph+ ALL, and the choice depends on prior treatments, response, tolerability, and specific disease factors.

Common alternative TKIs

• Imatinib (commonly used in CML)
• Nilotinib
• Bosutinib
• Ponatinib

Alternative choices may be considered if dasatinib is not tolerated, if there is inadequate response, or if interactions cannot be managed. Your treating team can explain why one option is preferred for your situation.

Market and legal context for Australia (patient-friendly overview)

In Australia, cancer medicines are regulated under the Therapeutic Goods Administration (TGA) framework. Availability can also depend on whether a medicine is listed on the Australian Pharmaceutical Benefits Scheme (PBS) and on eligibility criteria for specific medicines and indications.

Treatment access may involve medicines being supplied through public hospital systems, private oncology clinics, or via PBS-subsidised supply where eligible. Your pharmacy or treating team can explain how your specific supply pathway works.

Why this matters for patients

• Brand and strength availability may vary by supplier.
• Authorisation for supply can differ by indication and patient circumstances.
• Medication continuity is important in long-term cancer therapy—so planning refills matters.

Recent guidance and practical updates

Clinical guidance for CML and Ph+ ALL evolves as new evidence emerges about optimal sequencing, monitoring, and management of adverse effects. In particular, clinicians focus on:

• monitoring for fluid retention and cardiopulmonary effects
• managing drug-drug interactions (especially acid-reducing medicines and liver enzyme interactions)
• adjusting doses when side effects occur to maintain treatment benefit
• regular assessment of response using blood and molecular tests

For the most current recommendations in Australia, patients should rely on their oncology team’s advice and locally issued clinical guidance.

Delivery, availability, and packaging information

Availability of dasatinib can vary depending on your location and the strength/brand supplied. Our pharmacy aims to dispatch your medicine promptly once it is prepared and confirmed.

Delivery options (typical)

• Standard delivery: commonly within a few business days (varies by region)
• Express delivery: may be available for eligible areas
• Pickup options: may be offered in some stores

Packaging and storage

• Keep in original packaging: helps confirm the correct strength and expiry date.
• Store at controlled room temperature: follow the label instructions.
• Keep out of reach of children: cancer medicines require secure storage.

Refill planning

Dasatinib is often taken long-term. To avoid interruptions, order refills before you run out and factor in public holidays and delivery times.

FAQ (frequently asked questions)

1) What is dasatinib used for?

Dasatinib is used to treat certain cases of Philadelphia chromosome–positive CML and Ph+ ALL, depending on disease phase and patient history.

2) How quickly does dasatinib start working?

Some improvements may be noticed over weeks, but measurable molecular or blood responses are typically assessed over months using regular tests. Your clinician will set the monitoring schedule.

3) Can I take dasatinib with food?

Food may affect absorption. The safest approach is to follow the instructions provided for your specific product and regimen. If the pack or clinician advises taking with or without food, keep that routine consistent.

4) What medicines should I avoid?

Many medicines can interact, including certain antifungals/antibiotics (CYP3A4 inhibitors), some seizure or herbal products (CYP3A4 inducers), and some acid-reducing medications. Provide your complete list to your pharmacist before starting any new medicine.

5) Is it safe to drink alcohol while taking dasatinib?

Moderate alcohol use may be possible for some people, but heavy or frequent drinking can increase liver-related risks and worsen side effects. Ask your clinician for advice tailored to your health and liver function.

6) What side effects are most common?

Common side effects include fatigue, nausea, diarrhoea, rash, and lowered blood counts. Fluid retention and breathing-related symptoms can occur in some patients and should be reported promptly.

7) What should I do if I miss a dose?

Follow your regimen instructions. In general, avoid taking extra doses to “catch up” unless advised. If you are unsure, contact your pharmacy or healthcare team.

8) Do I need regular blood tests?

Yes. Monitoring blood counts and organ function is an important part of safety with TKIs, especially early in treatment and after dose changes.

9) Can I stop dasatinib if I feel better?

Do not stop or change treatment without discussion with your treating team. Response and disease control can change if therapy is interrupted.

10) Are there alternatives if I can’t tolerate dasatinib?

Yes. Other TKIs may be considered depending on your diagnosis, prior treatments, and side effect profile. Your treating team can discuss suitability and risks.

Important patient reminder

This information is designed to help you understand dasatinib and prepare for treatment discussions. Always follow the specific directions provided with your medicine and consult your healthcare team for personalised advice—especially if you have other medical conditions, liver issues, heart problems, or you take medicines that may interact.